Pioneering Multi-Pathway Modulators
Treating Cancer and Chronic Neurological Diseases
Triterpenoid Therapeutics (TTX) is developing brain-penetrant therapeutics that target root drivers of disease progression in neurodegenerative diseases and brain cancers, conditions that have resisted treatment for decades.
Targeting the NLRP3 Inflammasome and Integrated Stress Response (ISR)
A significant overlap of the NLRP3 Inflammasome and cellular Integrated Stress Response drives disease progression across multiple conditions, including neurodegenerative diseases and brain cancer. Understanding this interaction opens new therapeutic opportunities and is the focus of TTX’s efforts to improve patient outcomes.
A Pipeline of Proprietary Brain-Penetrant Small Molecules
TTX is advancing a pipeline of small molecule modulators that simultaneously suppress inflammatory signaling and enhance cellular antioxidant defenses. Our compounds target the NLRP3 Inflammasome and key regulators of the cellular Integrated Stress Response (ISR) that synergize to influence the progression of neurodegenerative diseases and therapy resistance in cancer.
